Shares of GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) dropped 6.5% on Thursday . The stock traded as low as $19.89 and last traded at $20.23. Approximately 1,838,334 shares traded hands during trading, an increase of 3,686% from the average daily volume of 48,553 shares. The stock had previously closed at $21.64.
GENMAB A/S/S Stock Performance
The firm’s 50-day moving average price is $21.19 and its 200 day moving average price is $24.08.
GENMAB A/S/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Recommended Stories
- Five stocks we like better than GENMAB A/S/S
- What is a Bond Market Holiday? How to Invest and Trade
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- ESG Stocks, What Investors Should Know
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- EV Stocks and How to Profit from Them
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
